Investing.comDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 06:40:40·⟳ 抓取 06:41:12 +32s·⚡ 决策 10-09 06:42:38 +1m26s·18.5 天前
Pharvaris（PHVS）HAE药物deucrictibant的RAPIDe-3三期结果登《柳叶刀》，但系旧顶线数据再发表
《柳叶刀》论文只是约10个月前（2025-12-03）已披露的RAPIDe-3阳性顶线数据的同行评议正式发表，主要终点、起效时间等关键数字市场早已获知，NDA/MAA审评状态亦无变化，缺乏可交易的增量信息。
📄 原文Investing.com↗ 原文
Pharvaris HAE drug shows faster symptom relief in Lancet study
By Investing.com Advertisement Advertisement Pharvaris HAE drug shows faster symptom relief in Lancet study Company New…
不做 Pharvaris N.V.（PHVS.US）
《柳叶刀》发表的是2025年12月3日已公布、且2026年6月EAACI已展示的RAPIDe-3顶线数据，无新增临床或监管事实，关键结论早已price-in；盘后股价微涨约0.5%、成交极清淡，印证缺乏可交易edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Pharvaris的HAE药物三期结果虽阳性并登上《柳叶刀》，但核心数据2025年12月已公布、2026年6月又在EAACI报告，本次仅为旧数据再发表，无预期差，故不做。
消息传播链
- 报道RAPIDe-3结果在《柳叶刀》正式发表，未含新临床或监管事实；盘后股价仅微涨约0.5%、成交极清淡，印证无新增edge
关键理由
- 本次事件无新增临床或监管事实：RAPIDe-3顶线结果2025-12-03已公布，数据2026-06-15已在EAACI展示
- NDA已在FDA审评中（目标行动日2027-04-23），《柳叶刀》发表不改变审评时间表或获批概率的市场预期
主要风险
- 若《柳叶刀》论文含此前未披露的亚组或安全性细节并引发媒体二次传播，可能带来短暂情绪波动，但基本面不变
- 股价近20日已跌约17%、处52周高位下方约28%，弱势股的弱催化不构成做多理由
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-08 · 影响 none
未发现《柳叶东》论文含此前未披露的重大新发现，NDA/MAA审评状态无变化
检索:deucrictibant RAPIDe-3 新增数据 安全性 亚组 Lancet 未披露 原文 ↗
先例如何影响了这次决策
对本次决策的影响:未改变结论：直接以NO_INCREMENTAL_FACT回避
方向:无可用对齐先例；但本事件核心问题是缺乏增量事实而非方向，先例不改变AVOID结论
涨幅量级:不足以用先例校准幅度，因催化本身为旧数据再发表
形态:未检索同类'顶线后同行评议发表'先例；盘后价量（微涨、低量）本身显示市场未视为新催化
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 15 ms
{"result": "search_processed_events:agent query=`pharvaris deucrictibant immediate-release capsule symptom relief | pharvaris deucrictibant rapide-3 lancet phase 3 results | phvs hereditary angioedema phase 3 topline nda`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表 - web_search 成功 doubao_search · 1,328 ms
豆包搜索结果（原始查询:Pharvaris RAPIDe-3 phase 3 topline results deucrictibant announcement 2025；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 1,594 ms
{ - web_search 成功 doubao_search · 1,551 ms
豆包搜索结果（原始查询:Pharvaris RAPIDe-3 topline results date press release primary endpoint met；API SearchType:web）
原文全文
展开原文 · 7,636 字
Pharvaris HAE drug shows faster symptom relief in Lancet study By Investing.com
Advertisement
Advertisement
Pharvaris HAE drug shows faster symptom relief in Lancet study
Company News
Published
Oct 08, 2026, 06:40 PM
Pharvaris HAE drug shows faster symptom relief in Lancet study
View all comments (0)
0
Pharvaris HAE drug shows faster symptom relief in Lancet study
View all comments (0)
0
© Reuters
In this article:
PHVS
-1.77%
ZUG, Switzerland - Pharvaris (
NASDAQ:PHVS
) announced today that results from its phase 3 RAPIDe-3 study of deucrictibant immediate-release capsule for hereditary angioedema attacks have been published in The Lancet, according to a press release statement.
The randomized, double-blind, placebo-controlled crossover study evaluated the oral 20 mg capsule for on-demand treatment of HAE attacks in adolescents and adults. Treatment with deucrictibant IR resulted in time to onset of symptom relief of 1.28 hours and time to complete symptom resolution of 11.95 hours.
The study met its primary endpoint and all 11 secondary endpoints with statistical significance. Deucrictibant IR achieved end of attack symptom progression, symptom relief, and complete symptom resolution faster than placebo. Most attacks were controlled with a single capsule. The drug showed a well-tolerated safety profile with no safety signals observed.
Results were consistent across subgroups defined by age, geographic location, HAE type including HAE with normal C1 inhibitor, use of long-term prophylaxis, and attack severity and location including non-severe laryngeal attacks.
"Bradykinin B2 receptor antagonism is a validated and reliable mechanism currently being widely used for the on-demand treatment of HAE attacks," said Marc A. Riedl, Professor of Medicine at the University of California San Diego and principal study investigator.
The RAPIDe-3 study is registered as NCT06343779. An open-label extension study, RAPIDe-2, is ongoing, and an expanded access program is available in the U.S. for eligible patients.
A New Drug Application for deucrictibant IR is under review with the FDA with a target action date of April 23, 2027. A Marketing Authorization Application is also under review with the European Medicines Agency.
Deucrictibant is an oral bradykinin B2 receptor antagonist being developed in two formulations: an extended-release tablet for prophylactic treatment and an immediate-release capsule for on-demand treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Pharvaris HAE drug shows faster symptom relief in Lancet study
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,285.90
+54.2
+0.11%
US 500
7,777.60
+12.1
+0.16%
Dow Jones
51,231.70
+51.83
+0.10%
S&P 500
7,765.47
-36.30
-0.47%
Nasdaq
27,193.34
-345.35
-1.25%
S&P 500 VIX
15.41
+0.33
+2.19%
Dollar Index
101.922
-0.008
-0.01%
Crude Oil WTI Futures
91.07
-0.42
-0.46%
Brent Oil Futures
104.13
+3.93
+3.92%
Natural Gas Futures
3.13
-0.040
-1.26%
Gold Futures
4,164.34
+7.34
+0.18%
Silver Futures
59.663
+0.242
+0.41%
Copper Futures
6.5625
-0.0075
-0.11%
US Soybeans Futures
1,286.50
0.00
0.00%
U.S. 10Y
5.227
-0.002
-0.04%
U.S. 30Y
5.607
0.000
0.00%
U.S. 5Y
4.993
+0.002
+0.04%
U.S. 3M
4.151
0.000
0.00%
US 10Y T-Note Futures
104.73
+0.02
+0.01%
Euro Bund Futures
121.19
+0.38
+0.31%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
340.42
+3.75
+1.11%
NVDA
230.48
-6.99
-2.94%
GOOGL
348.29
-2.21
-0.63%
TSLA
375.00
-2.81
-0.74%
AMZN
254.06
-5.86
-2.25%
NFLX
71.57
+1.87
+2.68%
META
720.89
-0.42
-0.06%
Advertisement
Most Popular Articles
News
Analysis
Nasdaq ends over 1% lower as tech stocks take a hit on OpenAI revenue report
By Investing.co
...
Oct 09, 2026
Oil settles below session high after Trump says no Iran attack before midterms
By Investing.co
...
Oct 09, 2026
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
By Investing.co
...
Oct 08, 2026
Why Citi says the Fed could be setting up for a dovish surprise
By Investing.co
...
Oct 08, 2026
TSMC Blowout Earnings: What This Means for Markets
By Lee Yang
Oct 09, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Oil Tops $100 as Stocks Come Under Pressure - Dow’s 50,000 Level Now in Focus
By Fawad Razaqz
...
Oct 08, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,035.85
-4.79%
25.61M
NVDA
230.48
-2.94%
109.06M
SNDK
1,609.46
-4.90%
8.97M
AMD
620.79
-3.88%
19.85M
INTC
107.13
-5.30%
104.63M
SPCX
160.57
-4.19%
65.12M
AAPL
340.42
+1.11%
30.25M
Name
Last
Chg. %
Vol.
CSGP
29.81
+8.01%
9.42M
GDDY
103.19
+6.15%
1.61M
CMG
32.65
+6.11%
63.69M
ACN
208.36
+5.96%
7.42M
IT
195.41
+5.19%
721.05K
CTSH
60.02
+5.17%
7.46M
EPAM
113.86
+5.11%
438.12K
Name
Last
Chg. %
Vol.
ALAB
346.90
-9.25%
5.28M
CRWV
81.58
-7.77%
41.30M
NBIS
219.71
-7.35%
21.10M
ARM
275.29
-6.48%
5.52M
GLW
152.83
-6.38%
7.94M
VST
156.14
-6.35%
10.58M
LITE
1,048.61
-5.62%
4.53M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,035.85
-4.79%
25.61M
NVDA
230.48
-2.94%
109.06M
SPCX
160.57
-4.19%
65.12M
APLD
23.850
+0.17%
54.59M
SNDK
1,609.46
-4.90%
8.97M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
Pharvaris HAE drug shows faster symptom relief in Lancet study
Company News
Published
Oct 08, 2026, 06:40 PM
Pharvaris HAE drug shows faster symptom relief in Lancet study
View all comments (0)
0
Pharvaris HAE drug shows faster symptom relief in Lancet study
View all comments (0)
0
© Reuters
In this article:
PHVS
-1.77%
ZUG, Switzerland - Pharvaris (
NASDAQ:PHVS
) announced today that results from its phase 3 RAPIDe-3 study of deucrictibant immediate-release capsule for hereditary angioedema attacks have been published in The Lancet, according to a press release statement.
The randomized, double-blind, placebo-controlled crossover study evaluated the oral 20 mg capsule for on-demand treatment of HAE attacks in adolescents and adults. Treatment with deucrictibant IR resulted in time to onset of symptom relief of 1.28 hours and time to complete symptom resolution of 11.95 hours.
The study met its primary endpoint and all 11 secondary endpoints with statistical significance. Deucrictibant IR achieved end of attack symptom progression, symptom relief, and complete symptom resolution faster than placebo. Most attacks were controlled with a single capsule. The drug showed a well-tolerated safety profile with no safety signals observed.
Results were consistent across subgroups defined by age, geographic location, HAE type including HAE with normal C1 inhibitor, use of long-term prophylaxis, and attack severity and location including non-severe laryngeal attacks.
"Bradykinin B2 receptor antagonism is a validated and reliable mechanism currently being widely used for the on-demand treatment of HAE attacks," said Marc A. Riedl, Professor of Medicine at the University of California San Diego and principal study investigator.
The RAPIDe-3 study is registered as NCT06343779. An open-label extension study, RAPIDe-2, is ongoing, and an expanded access program is available in the U.S. for eligible patients.
A New Drug Application for deucrictibant IR is under review with the FDA with a target action date of April 23, 2027. A Marketing Authorization Application is also under review with the European Medicines Agency.
Deucrictibant is an oral bradykinin B2 receptor antagonist being developed in two formulations: an extended-release tablet for prophylactic treatment and an immediate-release capsule for on-demand treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Pharvaris HAE drug shows faster symptom relief in Lancet study
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,285.90
+54.2
+0.11%
US 500
7,777.60
+12.1
+0.16%
Dow Jones
51,231.70
+51.83
+0.10%
S&P 500
7,765.47
-36.30
-0.47%
Nasdaq
27,193.34
-345.35
-1.25%
S&P 500 VIX
15.41
+0.33
+2.19%
Dollar Index
101.922
-0.008
-0.01%
Crude Oil WTI Futures
91.07
-0.42
-0.46%
Brent Oil Futures
104.13
+3.93
+3.92%
Natural Gas Futures
3.13
-0.040
-1.26%
Gold Futures
4,164.34
+7.34
+0.18%
Silver Futures
59.663
+0.242
+0.41%
Copper Futures
6.5625
-0.0075
-0.11%
US Soybeans Futures
1,286.50
0.00
0.00%
U.S. 10Y
5.227
-0.002
-0.04%
U.S. 30Y
5.607
0.000
0.00%
U.S. 5Y
4.993
+0.002
+0.04%
U.S. 3M
4.151
0.000
0.00%
US 10Y T-Note Futures
104.73
+0.02
+0.01%
Euro Bund Futures
121.19
+0.38
+0.31%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
340.42
+3.75
+1.11%
NVDA
230.48
-6.99
-2.94%
GOOGL
348.29
-2.21
-0.63%
TSLA
375.00
-2.81
-0.74%
AMZN
254.06
-5.86
-2.25%
NFLX
71.57
+1.87
+2.68%
META
720.89
-0.42
-0.06%
Advertisement
Most Popular Articles
News
Analysis
Nasdaq ends over 1% lower as tech stocks take a hit on OpenAI revenue report
By Investing.co
...
Oct 09, 2026
Oil settles below session high after Trump says no Iran attack before midterms
By Investing.co
...
Oct 09, 2026
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
By Investing.co
...
Oct 08, 2026
Why Citi says the Fed could be setting up for a dovish surprise
By Investing.co
...
Oct 08, 2026
TSMC Blowout Earnings: What This Means for Markets
By Lee Yang
Oct 09, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Oil Tops $100 as Stocks Come Under Pressure - Dow’s 50,000 Level Now in Focus
By Fawad Razaqz
...
Oct 08, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,035.85
-4.79%
25.61M
NVDA
230.48
-2.94%
109.06M
SNDK
1,609.46
-4.90%
8.97M
AMD
620.79
-3.88%
19.85M
INTC
107.13
-5.30%
104.63M
SPCX
160.57
-4.19%
65.12M
AAPL
340.42
+1.11%
30.25M
Name
Last
Chg. %
Vol.
CSGP
29.81
+8.01%
9.42M
GDDY
103.19
+6.15%
1.61M
CMG
32.65
+6.11%
63.69M
ACN
208.36
+5.96%
7.42M
IT
195.41
+5.19%
721.05K
CTSH
60.02
+5.17%
7.46M
EPAM
113.86
+5.11%
438.12K
Name
Last
Chg. %
Vol.
ALAB
346.90
-9.25%
5.28M
CRWV
81.58
-7.77%
41.30M
NBIS
219.71
-7.35%
21.10M
ARM
275.29
-6.48%
5.52M
GLW
152.83
-6.38%
7.94M
VST
156.14
-6.35%
10.58M
LITE
1,048.61
-5.62%
4.53M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,035.85
-4.79%
25.61M
NVDA
230.48
-2.94%
109.06M
SPCX
160.57
-4.19%
65.12M
APLD
23.850
+0.17%
54.59M
SNDK
1,609.46
-4.90%
8.97M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
d393677e19· 2026-10-09 06:42 · doubao / doubao-seed-evolving-latest-version · 策略包d5018cb8913f当前